Vetter Offers Sterile Water for Injection Syringes with Five Years Stability Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Offers Sterile Water for Injection Syringes with Five Years Stability Data
Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan.


Vetter, a contract development and manufacturing organization, announced that it is offering filling services for sterile water for injection syringes with five years stability data. The CMO’s stability data and bracketing concept allows a longer shelf life for drugs and high flexibility while defining the filling volume. Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan. Validation and stability data according to standard guidelines, such as the US Pharmacopeia, the European Pharmacopoeia and ICH, are also available.

The number of drugs that are sensitive to environmental influences is increasing. The formulations are often freeze dried to prolong shelf life and therefore require reconstitution in a suitable solvent before administration. Vetter filling service for syringes with sterile water for injection provides the solution for safe and simple reconstitution. The system contains the exact amount of solvent required by the customer to produce the required dosage, which helps assure that patients receive the exact amount of substance needed.

Vetter’s filling service for sterile water for injection syringes is available in 1.5 ml formats with a volume of 0.5 ml to 1.3 ml, as well as a 3 ml format with a volume of 1.4 ml to 3.0 ml. The syringe features Vetter’s V-OVS tamper-evident closure, which is designed to give a prefilled syringe system effective protection features. Vetter’s filling service comes with five years stability data and can manufacture batches of up to 140,000 pieces.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here